About this episode
In this episode the hosts dig into a $7.1?M cash?price listing for a specialty pharmacy in Beverly Hills — evaluating its 1.49?M?EBITDA, market position and regulatory complexity to see whether it’s a viable acquisition.Business Listing – https://www.bizbuysell.com/business-opportunity/specialty-medical-pharmacy-in-prime-southern-california-location/2445305/Welcome to Acquisitions Anonymous – the #1 podcast for small business M&A. Every week, we break down businesses for sale and talk about buying, operating, and growing them.? Sponsored by:Tonnesen Accounting Services - Tonnesen provides full quality of earnings reports trusted by buyers, lenders, and brokers on over $500 million in deals each year. Fast, detailed, and affordable. Visit tonnesenaccountingservices.com or connect with Josh Tonnesen on LinkedIn for a free consult.Capital Pad – A platform connecting accredited investors with vetted small business acquisition deals. Discover exclusive opportunities at https://capitalpad.comThis episode of Acquisitions Anonymous breaks down a real?world potential buy of a specialty (medical) pharmacy based in Beverly Hills, California. The listing claims a 2025 expected revenue of about $6.2?M with $1.49?M in EBITDA/SDE, monthly rent around $9,167, and an asking price of $7.1?M — roughly 4.75× trailing earnings. The sellers are motivated by acute health issues and retirement, which introduces urgency. The hosts explore both the upside — a long?established business in a wealthy market, high margins, and niche specialty?pharmacy demand — and the downsides: regulatory/licensure hurdles, dependence on skilled pharmacists, insurance/payer access challenges, and the uncertainty of consistency in earnings.Key Highlights:- Asking price: $7.1?M cash, with stated EBITDA/SDE of $1.49?M ? ~4.75× multiple.- Business profile: Long?established (since ~1980), located in affluent Beverly Hills, servicing specialty prescriptions (potentially high?cost biologics, pain, immunology, chemo) rather than typical retail offerings. - Opportunity: High margins (claimed ~25%) — above what might be expected for a typical low?margin compounding pharmacy. - Risks: Regulatory/licensure risk under the California pharmacy law: any change in ownership or control requires approval by the board before the transaction can close. - Execution risk: Because the seller is reportedly ill and likely a “forced seller,” there may be pressure to close quickly — which compresses time for due diligence on payer contracts, referral sources, license transfers, and underlying quality-of-earnings. Subscribe to weekly our Newsletter and get curated deals in your inboxAdvertise with us by clicking here Do you love Acquanon and want to see our smiling faces? Subsc
